6.
Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H
. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637.
PMC: 7251107.
DOI: 10.1038/s41416-020-0802-1.
View
7.
Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson N
. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014; 123(11):1699-708.
PMC: 3954051.
DOI: 10.1182/blood-2013-07-509885.
View
8.
Benati M, Montagnana M, Danese E, Paviati E, Giudici S, Franchi M
. Evaluation of mir-203 Expression Levels and DNA Promoter Methylation Status in Serum of Patients with Endometrial Cancer. Clin Lab. 2017; 63(10):1675-1681.
DOI: 10.7754/Clin.Lab.2017.170421.
View
9.
Lawrie C, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S
. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009; 13(7):1248-60.
PMC: 4496139.
DOI: 10.1111/j.1582-4934.2008.00628.x.
View
10.
Gong J, Cong M, Wu H, Wang M, Bai H, Wang J
. P53/miR-34a/SIRT1 positive feedback loop regulates the termination of liver regeneration. Aging (Albany NY). 2023; 15(6):1859-1877.
PMC: 10085612.
DOI: 10.18632/aging.203920.
View
11.
Huang W, Paul D, Calin G, Bayraktar R
. miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities. Cells. 2024; 13(1).
PMC: 10778542.
DOI: 10.3390/cells13010084.
View
12.
Wong K, Yim R, Kwong Y, Leung C, Hui P, Cheung F
. Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol. 2013; 6:16.
PMC: 3576298.
DOI: 10.1186/1756-8722-6-16.
View
13.
Sargolzaei J, Etemadi T, Alyasin A
. The P53/microRNA network: A potential tumor suppressor with a role in anticancer therapy. Pharmacol Res. 2020; 160:105179.
DOI: 10.1016/j.phrs.2020.105179.
View
14.
Fiskvik I, Aamot H, Delabie J, Smeland E, Stokke T, Heim S
. Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. Eur J Haematol. 2013; 91(4):332-8.
DOI: 10.1111/ejh.12171.
View
15.
Urbanek-Trzeciak M, Galka-Marciniak P, Nawrocka P, Kowal E, Szwec S, Giefing M
. Pan-cancer analysis of somatic mutations in miRNA genes. EBioMedicine. 2020; 61:103051.
PMC: 7648123.
DOI: 10.1016/j.ebiom.2020.103051.
View
16.
Taylor A, Shih J, Ha G, Gao G, Zhang X, Berger A
. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018; 33(4):676-689.e3.
PMC: 6028190.
DOI: 10.1016/j.ccell.2018.03.007.
View
17.
Cabrita M, Vanzyl E, Hamill J, Pan E, Marcellus K, Tolls V
. A Temperature Sensitive Variant of p53 Drives p53-Dependent MicroRNA Expression without Evidence of Widespread Post-Transcriptional Gene Silencing. PLoS One. 2016; 11(2):e0148529.
PMC: 4739602.
DOI: 10.1371/journal.pone.0148529.
View
18.
Munch-Petersen H, Asmar F, Dimopoulos K, Areskeviciute A, Brown P, Girkov M
. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol Commun. 2016; 4:40.
PMC: 4840983.
DOI: 10.1186/s40478-016-0307-6.
View
19.
Ricketts S, Carter J, Coleman W
. Identification of three 11p11.2 candidate liver tumor suppressors through analysis of known human genes. Mol Carcinog. 2003; 36(2):90-9.
DOI: 10.1002/mc.10101.
View
20.
Talotta D, Almasri M, Cosentino C, Gaidano G, Moia R
. Liquid biopsy in hematological malignancies: current and future applications. Front Oncol. 2023; 13:1164517.
PMC: 10157039.
DOI: 10.3389/fonc.2023.1164517.
View